Welcome!

News Feed Item

Cumberland Pharmaceuticals Reports 2013 Fourth Quarter And Annual Financial Results

- Acquired Vaprisol® from Astellas Pharma US, Inc.

NASHVILLE, Tenn., March 4, 2014 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology, today announced fourth quarter and annual 2013 financial results. The Company also recently announced the acquisition of Vaprisol, a marketed critical care product from Astellas Pharma US, Inc.

Net Revenue:  For the three months ended December 31, 2013, net revenue was $8.2 million, compared to $13.7 million for the prior year period.  Net revenue was $3.7 million for Acetadote® including $2.2 million from our authorized generic, $2.8 million for Kristalose®, $0.6 million for Caldolor®, and $1.0 million for our new product, Omeclamox®-Pak.

For the year ended December 31, 2013, net revenues were $32.0 million, compared with $48.9 million for 2012.

Operating Expenses:  Total operating expenses for the three months ended December 31, 2013 were $10.6 million compared to $10.4 million the prior year period.

For the year ended December 31, 2013, total operating expenses were approximately $35.8 million compared with $40.0 million for 2012.

Net (Loss) Income:  Net (loss) income attributable to common shareholders for the three months ended December 31, 2013 was a net loss of $1.5 million, or $(0.08) per diluted share, compared to net income of $1.8 million, or $0.09 per diluted share, for the same period in 2012.

Net (loss) income attributable to common shareholders for the year ended December 31, 2013 was a net loss of $2.1 million, or $(0.11) per diluted share, compared to net income of $5.8 million, or $0.30 per diluted share, for 2012.

Balance Sheet:  As of December 31, 2013, cash and marketable securities were $54.9 million, compared to $71.0 million at the end of the prior year. Total assets at December 31, 2013, were $87.6 million compared to $98.6 million at the end of 2012. As of December 31, 2013, the revolving line of credit had been fully paid compared to our balance of $4.4 million at the end of 2012.

"The Company encountered new challenges in 2013 and I am pleased to report that our team rose to the occasion," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "Our strategic theme for 2014 is to continue to build a diversified specialty product portfolio while deploying our resources to sustain long-term profitability. We will continue to focus on our mission of improving patient care through the delivery of high quality pharmaceutical products."

Product Highlights

Vaprisol®

Cumberland recently announced the acquisition of Vaprisol from Astellas Pharma US, Inc.  Vaprisol is a patented, prescription brand indicated to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia. The product was developed and registered by Astellas and commercially launched in 2006. It is one of two branded prescription products indicated for the treatment of hyponatremia.

The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion.  Vaprisol does not require dilution and has a well-defined daily dose of 10 mg, 20 mg, or 40 mg. 

Under the terms of the deal, Cumberland will assume full responsibility for the product including its marketing, distribution and manufacture. Cumberland will promote Vaprisol across the United States through its hospital sales force, which also features its Caldolor and Acetadote brands.

Omeclamox®-Pak

Cumberland announced during the fourth quarter, an agreement with Pernix Therapeutics LLC for the promotion of Omeclamox-Pak covering the United States. Omeclamox-Pak is a branded prescription product that combines omeprazole, amoxicillin and clarithromycin for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease. It is the only FDA approved triple combination medication to contain omeprazole as the proton pump inhibitor and is prescribed over a shortened treatment period of ten days.

Under the terms of the agreement, Cumberland will promote the product to gastroenterologists across the United States through its field sales force, which also promotes its Kristalose brand. Pernix will promote the product through its specialty sales force focusing on select primary care physicians. The companies will cooperate in the marketing and other activities needed to support the commercialization of the brand.

Conference Call and Webcast

A conference call and live Internet webcast will be held on Tuesday, March 4, 2014 at 4:30 p.m. Eastern Time to discuss the Company's fourth quarter and annual 2013 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 4339060. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.

About Cumberland Pharmaceuticals

Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose® (lactulose) for Oral Solution, a prescription laxative, Omeclamox-Pak® for the treatment of H. pylori and duodenal ulcer disease and Vaprisol®, an intravenous treatment for hyponatremia. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information on Cumberland, please visit the Company's website at www.cumberlandpharma.com.

About Acetadote

Acetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted, fluid overload can occur, potentially resulting in hyponatremia, seizure and death.  For full prescribing information, visit www.acetadote.com.

About Caldolor

Caldolor is indicated for the management of mild to moderate pain and management of moderate to severe pain as an adjunct to opioid analgesics, as well as the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor.  For full prescribing information, including boxed warning, visit www.caldolor.com.

About Kristalose

Kristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient.  Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.

About Omeclamox-Pak

Omeprazole is an antisecretory drug, which works by decreasing the amount of acid the stomach produces. Clarithromycin and amoxicillin are antibacterial drugs, which inhibit the growth of bacteria allowing the stomach lining to heal. Omeclamox-Pak is contraindicated in patients with a history of hypersensitivity to omeprazole, any macrolide antibiotic or penicillin. The safety and effectiveness of Omeclamox-Pak in the pediatric population has not yet been established. Omeclamox-Pak was approved by the U.S. Food and Drug Administration in 2011. For full prescribing information, visit www.omeclamox.com.

About Vaprisol

Vaprisol an intravenous treatment for hyponatremia used in the critical care setting. Hyponatremia is an electrolyte disturbance in which sodium ion concentration in blood plasma is lower than normal.  This can be associated with a variety of critical care conditions including congestive heart failure, liver failure, kidney failure and pneumonia.  The product is a vasopressin receptor antagonist that raises serum sodium levels and promotes free water secretion. Vaprisol was approved by the U.S. Food and Drug Administration in 2005 for euvolemic hyponatremia and in 2007 for hypervolemic hyponatremia. For full prescribing information, visit www.vaprisol.com.

Forward-Looking Statements

This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's most recent Form 10-K and subsequent 10-Q's as filed with the SEC. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.

 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited)

December 31, 2013 and 2012




2013


2012






ASSETS





Current assets:





Cash and cash equivalents


$

40,869,457



$

54,349,381


Marketable securities


14,019,761



16,686,136


Accounts receivable, net of allowances


4,530,424



6,017,201


Inventories


5,722,882



6,218,355


Prepaid and other current assets


825,675



1,671,091


Deferred tax assets


2,711,516



2,290,078


Total current assets


68,679,715



87,232,242


Property and equipment, net


880,647



1,188,914


Intangible assets, net


15,498,819



9,476,798


Deferred tax assets


1,208,891



50,411


Other assets


1,345,666



645,366


Total assets


$

87,613,738



$

98,593,731







LIABILITIES AND EQUITY





Current liabilities:





Accounts payable


$

2,035,853



$

2,790,554


Other current liabilities


5,509,917



5,264,806


Total current liabilities


7,545,770



8,055,360


Revolving line of credit




4,359,951


Other long-term liabilities


776,125



611,933


Total liabilities


8,321,895



13,027,244


Commitments and contingencies





Equity:





Shareholders' equity:





Common stock – no par value; 100,000,000 shares authorized;

17,985,503 and 18,937,107 shares issued and outstanding as of

December 31, 2013 and 2012, respectively


63,073,941



67,197,167


Retained earnings


16,394,540



18,499,154


Total shareholders' equity


79,468,481



85,696,321


Noncontrolling interests


(176,638)



(129,834)


Total equity


79,291,843



85,566,487


Total liabilities and equity


$

87,613,738



$

98,593,731


 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES

Consolidated Statements of Operations and Comprehensive (Loss) Income

(Unaudited)




Three months ended

December 31,


Years ended

December 31,



2013


2012


2013


2012










Revenues:









Net product revenue


$

8,054,928



$

13,637,333



$

31,100,698



$

47,944,031


Other revenue


104,739



59,033



926,764



907,206


Net revenues


8,159,667



13,696,366



32,027,462



48,851,237


Costs and expenses:









Cost of products sold


2,145,011



2,172,762



5,439,422



5,046,179


Selling and marketing


3,761,552



4,942,425



14,387,745



20,329,493


Research and development


1,339,295



441,215



5,615,501



5,095,172


General and administrative


3,100,407



2,752,567



9,489,976



9,055,959


Amortization


285,479



134,404



896,156



506,332


Total costs and expenses


10,631,744



10,443,373



35,828,800



40,033,135


Operating (loss) income


(2,472,077)



3,252,993



(3,801,338)



8,818,102


Interest income


68,582



48,791



230,291



304,865


Interest expense


(40,701)



(15,616)



(103,422)



(71,985)


(Loss) income before income taxes


(2,444,196)



3,286,168



(3,674,469)



9,050,982


Income tax benefit (expense)


932,801



(1,492,213)



1,523,051



(3,244,776)


Net (loss) income


(1,511,395)



1,793,955



(2,151,418)



5,806,206


Net loss at subsidiary attributable to

 noncontrolling interests


11,032



11,545



46,804



36,286


Net (loss) income attributable to

 common shareholders


$

(1,500,363)



$

1,805,500



$

(2,104,614)



$

5,842,492











Earnings (loss) per share attributable to

 common shareholders:









Basic


$

(0.08)



$

0.09



$

(0.11)



$

0.30


Diluted


$

(0.08)



$

0.09



$

(0.11)



$

0.30


Weighted-average common shares outstanding:









Basic


18,072,805



19,048,945



18,332,997



19,564,625


Diluted


18,072,805



19,245,047



18,332,997



19,787,537











Comprehensive (loss) income


$

(1,511,395)



$

1,793,955



$

(2,151,418)



$

5,806,206











 

CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIES


Condensed Consolidated Statements of Cash Flows


(Unaudited)


Years ended December 31, 2013 and 2012






2013


2012








Cash flows from operating activities:






Net (loss) income


$

(2,151,418)



$

5,806,206



Adjustments to reconcile net (loss) income to net cash flows

 provided by operating activities:






Depreciation and amortization expense


1,301,835



901,649



Deferred tax benefit


(1,579,918)



(829,846)



Share-based compensation


674,955



636,528



Excess tax benefit derived from exercise of stock options


(48,024)



(3,760,766)



Noncash interest expense


24,075



24,075



Noncash investment losses (gains)


178,822



(45,814)



Net changes in assets and liabilities affecting operating activities:






Accounts receivable


1,486,777



1,065,689



Inventories


495,473



(443,661)



Prepaid, other current assets and other assets


117,021



(648,941)



Accounts payable and other accrued liabilities


58,855



4,373,276



Other long-term liabilities


187,673



56,787



Net cash provided by operating activities


746,126



7,135,182



Cash flows from investing activities:






Additions to property and equipment


(97,412)



(464,893)



Additions to intangible assets


(7,462,080)



(2,071,926)



Proceeds from sale of marketable securities


6,859,061



5,220,480



Purchases of marketable securities


(4,371,508)



(21,860,802)



Net cash used in investing activities


(5,071,939)



(19,177,141)



Cash flows from financing activities:






Net repayments on line of credit


(4,359,951)



(500,000)



Repurchase of common shares


(4,800,908)



(8,086,594)



Exercise of stock options


(41,276)



618,022



Excess tax benefit derived from exercise of stock options


48,024



3,760,766



Net cash used in financing activities


(9,154,111)



(4,207,806)



Net decrease in cash and cash equivalents


(13,479,924)



(16,249,765)



Cash and cash equivalents, beginning of year


54,349,381



70,599,146



Cash and cash equivalents, end of year


$

40,869,457



$

54,349,381



 

SOURCE Cumberland Pharmaceuticals Inc.

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
IoT solutions exploit operational data generated by Internet-connected smart “things” for the purpose of gaining operational insight and producing “better outcomes” (for example, create new business models, eliminate unscheduled maintenance, etc.). The explosive proliferation of IoT solutions will result in an exponential growth in the volume of IoT data, precipitating significant Information Governance issues: who owns the IoT data, what are the rights/duties of IoT solutions adopters towards t...
Today we can collect lots and lots of performance data. We build beautiful dashboards and even have fancy query languages to access and transform the data. Still performance data is a secret language only a couple of people understand. The more business becomes digital the more stakeholders are interested in this data including how it relates to business. Some of these people have never used a monitoring tool before. They have a question on their mind like “How is my application doing” but no id...
With the introduction of IoT and Smart Living in every aspect of our lives, one question has become relevant: What are the security implications? To answer this, first we have to look and explore the security models of the technologies that IoT is founded upon. In his session at @ThingsExpo, Nevi Kaja, a Research Engineer at Ford Motor Company, discussed some of the security challenges of the IoT infrastructure and related how these aspects impact Smart Living. The material was delivered interac...
The current age of digital transformation means that IT organizations must adapt their toolset to cover all digital experiences, beyond just the end users’. Today’s businesses can no longer focus solely on the digital interactions they manage with employees or customers; they must now contend with non-traditional factors. Whether it's the power of brand to make or break a company, the need to monitor across all locations 24/7, or the ability to proactively resolve issues, companies must adapt to...
Wooed by the promise of faster innovation, lower TCO, and greater agility, businesses of every shape and size have embraced the cloud at every layer of the IT stack – from apps to file sharing to infrastructure. The typical organization currently uses more than a dozen sanctioned cloud apps and will shift more than half of all workloads to the cloud by 2018. Such cloud investments have delivered measurable benefits. But they’ve also resulted in some unintended side-effects: complexity and risk. ...
It is ironic, but perhaps not unexpected, that many organizations who want the benefits of using an Agile approach to deliver software use a waterfall approach to adopting Agile practices: they form plans, they set milestones, and they measure progress by how many teams they have engaged. Old habits die hard, but like most waterfall software projects, most waterfall-style Agile adoption efforts fail to produce the results desired. The problem is that to get the results they want, they have to ch...
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, Doug Vanderweide, an instructor at Linux Academy, discussed why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers wit...
The taxi industry never saw Uber coming. Startups are a threat to incumbents like never before, and a major enabler for startups is that they are instantly “cloud ready.” If innovation moves at the pace of IT, then your company is in trouble. Why? Because your data center will not keep up with frenetic pace AWS, Microsoft and Google are rolling out new capabilities. In his session at 20th Cloud Expo, Don Browning, VP of Cloud Architecture at Turner, posited that disruption is inevitable for comp...
While DevOps most critically and famously fosters collaboration, communication, and integration through cultural change, culture is more of an output than an input. In order to actively drive cultural evolution, organizations must make substantial organizational and process changes, and adopt new technologies, to encourage a DevOps culture. Moderated by Andi Mann, panelists discussed how to balance these three pillars of DevOps, where to focus attention (and resources), where organizations might...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
In the world of DevOps there are ‘known good practices’ – aka ‘patterns’ – and ‘known bad practices’ – aka ‘anti-patterns.' Many of these patterns and anti-patterns have been developed from real world experience, especially by the early adopters of DevOps theory; but many are more feasible in theory than in practice, especially for more recent entrants to the DevOps scene. In this power panel at @DevOpsSummit at 18th Cloud Expo, moderated by DevOps Conference Chair Andi Mann, panelists discussed...
Cloud applications are seeing a deluge of requests to support the exploding advanced analytics market. “Open analytics” is the emerging strategy to deliver that data through an open data access layer, in the cloud, to be directly consumed by external analytics tools and popular programming languages. An increasing number of data engineers and data scientists use a variety of platforms and advanced analytics languages such as SAS, R, Python and Java, as well as frameworks such as Hadoop and Spark...